OPTHF

Optimi Health Corp.

Optimi Health Applauds Health Canada’s Position on Drug Quality and Goods and Manufacturing Practices (GMP) for Psilocybin

VANCOUVER, British Columbia, May 09, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) CEO, Bill Ciprick, issued a statement today in response to Health Canada’s May 6 Notice to Stakeholders “regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the... Read More...

Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility

VANCOUVER, British Columbia, April 28, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members of the media, investors and other stakeholders... Read More...

Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials

Optimi Health Corp.VANCOUVER, British Columbia, March 18, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.“These mushrooms are an important milest... Read More...

Optimi Health Announces Investor Relations Agreement

VANCOUVER, British Columbia, March 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce it has entered into agreements with Kydde... Read More...

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

Optimi Health Corp.VANCOUVER, British Columbia, Feb. 16, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has ad... Read More...

Optimi Health Dealer’s License Granted by Health Canada

Optimi Health to become a global leader in all-natural psilocybin productionVANCOUVER, British Columbia, Feb. 07, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellne... Read More...

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent

VANCOUVER, British Columbia, Jan. 18, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a propriet... Read More...

Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department

VANCOUVER, British Columbia, Dec. 21, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce a facility inspection under ... Read More...

Optimi Health Strengthens Clinical and Regulatory Expertise

VANCOUVER, British Columbia, July 27, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate regulatory submissions and planning relevant t... Read More...

Optimi Health Initiates Pathway to Nasdaq Listing

VANCOUVER, British Columbia, July 07, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products announced today that it has engaged the consulting services of Donohoe Advisory Associates LLC (“Donohoe Advisory”) to explore strategies to advance towar... Read More...